Log in


Upcoming Events

    • 10 Nov 2020
    • 3:00 PM - 4:30 PM (EST)
    • Webinar
    Register
    Canadian Pain Task Force: Present and Future - Quest for a National Pain Strategy


    Join us for an update on the work of the Canadian Pain Task Force. 

    DATE Wednesday, November 18, 2020

    TIME Newfoundland: 4:30 - 6:00 pm  |  Atlantic: 4:00 - 5:30 pm  |  Eastern: 3:00 - 4:30 pm  Mountain: 1:00 - 2:30 pm  |  Pacific: 12:00 - 1:30 pm

    All speakers consented to session being recorded in our planning meeting.

    Speakers 

    Fiona Campbell, BSc MD FRCA

    Dr. Campbell holds the rank of Professor in the Department of Anesthesiology and Pain Medicine at the University of Toronto, and is Medical Director of the Chronic Pain Program in the Department of Anesthesia & Pain Medicine at the Hospital for Sick Children (SickKids). As Co-Director of the SickKids Pain Centre Fiona is one of the SKIP Hub co-leads (Solutions for Kids in Pain – kidsinpain.ca), and is involved in developing strategic initiatives to improve pain outcomes for children. Fiona helped spearhead the SickKids successful application for ChildKind certification in 2014 – the first Canadian Children’s hospital to achieve this status; she is now a member of the ChildKind Certification Committee. Her research interests include: knowledge translation on pain in children and factors influencing the transition from acute to chronic pain. Dr Campbell co-chaired the International Guideline Development Group for Pain in Children with Cancer, and has co-created globally accessible self-management pain apps, interactive pain educational modules, and a pain education website for children and families. She is a Mayday Fellow.

    As the inaugural co-chair of the provincial Ontario Chronic Pain Network (Pediatric section) in partnership with Ontario Health, Dr Campbell has helped build capacity in the community by increasing access to pediatric chronic pain clinics, reducing disparities in care, standardizing model of care, and fostering research and education.

    Having been appointed by the Federal Minister of Health in 2019 to be Co-chair of the Canadian Pain Task Force, Fiona is an advocate for the implementation of a Canadian National Pain Strategy. 

    @DrFCampbell


    Maria Hudspith

    Maria is the Executive Director of Pain BC, a registered charity that works to enhance the lives of all people who live with pain through empowerment, care, education and innovation.

    In 2019, she was appointed co-chair of the Canadian Pain Task Force, mandated by the federal government to advise on an improved approach to pain care, education, research and data in Canada. She is one of the co-Principal Investigators for the CIHR-funded Chronic Pain Network and co-leads the Network’s Patient Engagement initiatives.

    Maria has led various community development, organizational change and capacity building initiatives in the health and non-profit sectors over the last 25 years, working in a number of fields at the nexus of equity, social movements and health justice.

     @PainBC


    Andrew Taylor

    Andrew Taylor is currently Acting Director of the Canadian Pain Task Force Secretariat, which is a part of the Controlled Substances and Cannabis Branch at Health Canada. The Task Force has a three year mandate to provide advice to Health Canada regarding evidence and best practices for the prevention and management of chronic pain. Prior to this role, Andrew led horizon scanning and foresight activities for the Health Canada’s Health Products and Food Branch.

    Prior to government, Andrew focused extensively on knowledge synthesis and translation as well as stakeholder engagement across a wide range of health policy topics, serving in several positions at institutions such as the Canadian Institutes for Health Research, Council of Canadian Academies, Canadian Institute for Health Information, Canadian Healthcare Association, Centre for Addiction and Mental Health, and AIDS Committee of Toronto.


    Jaris Swidrovich, BSP, PharmD, PhD(c)

    Dr. Jaris Swidrovich is an Assistant Professor in the College of Pharmacy and Nutrition at the University of Saskatchewan. He is a Two Spirit Saulteaux First Nations and Ukrainian man and pharmacist from Yellow Quill First Nation. Dr. Swidrovich is the first self-identified First Nations Doctor of Pharmacy in Canada and the first and only self-identified Indigenous faculty member across all ten faculties of pharmacy in Canada.

    He received a Bachelor of Science in Pharmacy (BSP) from the University of Saskatchewan, a Doctor of Pharmacy (PharmD) from the University of Toronto, and is currently a PhD Candidate in Education at the University of Saskatchewan. His areas of research and practice include HIV/AIDS, pain, substance use disorders, 2SLGBTQ+ health, Indigenous health, social determinants of health, pharmacy practice, and pharmacy / health professions education.

     @JarisSwidrovich

    Linda Wilhelm

    Linda Wilhelm is the President of The Canadian Arthritis Patient Alliance, a national, volunteer, patient driven organization that has worked to improve the lives of people living with arthritis since 2002. She is co-chair of the Steering Committee for the Chronic Pain Strategy for Patient Oriented Research (SPOR) Network, as well as a member of the networks patient advisory committee. She is also a member of The Evidence Alliance (SPOR) Network. Linda has participated in past Health Canada expert advisory panels and numerous conferences concerning treatment access and drug safety issues. She is a former member of both the Expert Advisory Committee for Vigilance of Health Products and the Drug Safety and Effectiveness Network's steering committee and a current member of The National Pain Taskforce.

    Ms. Wilhelm has been an active advocate for treatment access and quality of care for all patients both regionally and nationally for over twenty years and is a past board chair for the New Brunswick Division of the Arthritis Society. Ms. Wilhelm has been living with Rheumatoid Arthritis for over thirty five years, many of those years unresponsive to the medications used to treat the disease which resulted in significant and irreversible damage to most of the joints in her body leaving her to manage chronic pain on a daily basis and throughout her recovery from fourteen major joint reconstructive surgeries.

    Ms. Wilhelm is a recipient of the Queen’s Jubilee Golden and Diamond Medals of honour and the 2015 Arthritis Alliance of Canada Qualman/Davies Patient and Consumer Leadership Award.


    ******************************

    The CPS wishes to thank supporters of the full CPS+ Webinar Program

       

    This CPS+ Webinar is also kindly supported by


     

    Have questions? Check out our FAQs HERE, or email us at office@canadianpainsociety.ca

    @canadianpain
    #CPSPlus  #CanadianPain20




    • 10 Nov 2020
    • 3:00 PM - 4:30 PM (EST)
    • Webinar
    Register
    Pharmacogenomics for Personalized Pain Medicine


    DATE Tuesday, November 10, 2020

    TIME Newfoundland: 4:30 - 6:00 pm  |  Atlantic: 4:00 - 5:30 pm  |  Eastern: 3:00 - 4:30 pm  Mountain: 1:00 - 2:30 pm  |  Pacific: 12:00 - 1:30 pm

    Pharmacogenomic (PGx) testing has the potential to accelerate pharmacological response and improve outcomes for patients with pain. PGx is the study of the role of the genome in drug response, with a focus on genetic variants that affect pharmacokinetics (e.g. absorption, distribution, metabolism, elimination) and pharmacodynamics (e.g. receptor binding and chemical interactions). Approximately 60% of variation in individual responses to pain medications relate to genetic polymorphisms. Genes encode receptors on which drugs act, for example, the three classic opioid receptors (mu, kappa and delta). Many promising gene tests may have future clinical application. The Clinical Pharmacogenomics Implementation Consortium (CPIC) has created peer reviewed, evidence-based, updatable, and detailed gene/drug clinical practice guidelines with recommendations for prescribing actions if there are sufficient evidence. Medications used for chronic pain with existing CPIC prescribing actions assigned include amitriptyline, nortriptyline, carbamazepine, oxcarbazepine, tramadol, oxycodone, codeine and venlafaxine. With many available tests commercially available to patients, PGx is emerging as another tool for patients with chronic pain and their prescribers for shared decision-making, predicting response to drugs in situations where poor outcomes have occurred previously, and guiding dose titration. Despite the vast potential for pharmacogenomics to tailor the management of pain and improve patient outcomes, many barriers to its implementation exist, including the limited strength of available evidence, cost, turnaround time, and prescribers’ lack of familiarity with interpretation of test results.

    All speakers consented to session being recorded in our planning meeting.

    Speakers 

     Katherine Siminovitch, M.D., FRCP(C)

    Katherine Siminovitch is the Director of the Lunenfeld’s Genomic Medicine Program and the Clinical Genomics Centre and the Fred A. Litwin Family Centre of Genetic Medicine at Mount Sinai Hospital and University Health Network. She is the Chief Science Advisor at InageneTM. She will outline the basics of the science of pharmacogenomics (PGx) and explore current testing available for patients with pain. Dr. Siminovitch will also provide insight into the future promise of PGx for pain medicine with the array of genes that may hold answers to clinical questions.  Read more


    Laura Murphy, BScPhm, PharmD, MSc, RPh

    Laura Murphy is a Pharmacist in the Comprehensive Integrated Pain Program, working with patients with chronic pain and complex medication issues, and a Pharmacy Clinical Leader at University Health Network (UHN). She is a member of the Project ECHO Ontario Chronic Pain and Opioid Stewardship team, the Expert Advisory Panel of the Canadian Pain Task Force, and co-chair of the University of Toronto Centre for the Study of Pain’s Interfaculty Pain Curriculum. Her research is focused on pharmacy practice and opioids and cannabis for chronic pain. Read more

     @LmPharmd


    Moderator

    Andrea Furlan, MD, PhD, MD, PhD

    Andrea Furlan is a Physiatrist and senior scientist at Toronto Rehab UHN, and Associate Professor of Medicine at the University of Toronto. 

    Dr. Furlan is an early adopter of pharmacogenomics (PGx), recommending testing to patients with chronic pain in her clinic to support medication management. Thus far, many patients have been very interested in PGx testing, sometimes seeking it out on their own and often paying out of pocket. Despite this perceived interest from patients, we have identified many barriers to implementation in our clinic and for pain medicine on a broader level. Among other challenges, there is a strong need for education for physicians and other healthcare providers.  Read more

     @adfurlan

    ******************************

    The CPS wishes to thank supporters of the full CPS+ Webinar Program

       


     

    Have questions? Check out our FAQs HERE, or email us at office@canadianpainsociety.ca

    @canadianpain
    #CPSPlus  #CanadianPain20

**CPS reserves the right to cancel or change speakers, program content and date without prior notice. We assume no liability for these changes.**

Contact Us

office@canadianpainsociety.ca
+1-416-642-6379
301 - 250 Consumers Road, Toronto ON  M2J 4V6

Copyright ©2020

Powered by Wild Apricot Membership Software